ABSTRACT
Objective: To investigate the characteristics of magnetic resonance imaging (MRI) for primary hepatic fibrosarcoma so as to enhance the cognition for primary hepatic fibrosarcoma. Methods: The clinical documents, laboratory data and manifestations of MRI and pathology of 1 patient with primary hepatic fibrosarcoma were researched by using retrospective analysis, and the previously relevant literatures were combined to analyze and summarize MRI imaging characteristic of primary hepatic fibrosarcoma. Results: The primary hepatic fibrosarcoma has series of characteristics included of lower incidence, wider range of age, usual occurrence in male, without hepatitis history and background of liver cirrhosis, without specificity on clinical symptoms, sign and laboratory examination, and with symptoms of stomachache and glycopenia in part of patients. And the manifestations of MRI included that liver has larger phyma, and the most of boundary of phyma were clearness, and the necrosis, cystic change and bleeding could be found in inner of phyma, and there was no calcification, and hematogenous metastasis often occurred and lymphatic metastasis was rare. The enhanced scan showed that tumor wall, tumor septa and solid component have been continuously enhanced. And the pathological manifestation of primary hepatic fibrosarcoma showed that it was spindle cell sarcoma. And the results of immunohistochemistry indicated that alpha fetoprotein (AFP) was (-), and smooth muscle actin (SMA) was (+) and vimentin was (+). Conclusion: Hepatic fibrosarcoma is rare in clinical practice, but its malignancy is pretty high and its prognosis is poor. To enhance the cognition about the characteristics of MRI about primary hepatic fibrosarcoma would contribute to correctly diagnose it.
ABSTRACT
The purpose of this study was to investigate the effects of Celecoxib on the proliferation of the FLT3-ITD positive and negative acute myeloid leukemia cells and its mechanism. The proliferation inhibition effect of Celecoxib with different doses on the FLT3-ITD positive cells MV4-11 and the FLT3-ITD negative K562 cells was detected by CCK-8 method, the cell apoptosis was determined by flow cytometry, and the MEK, Mcl-1, pAKT expression was tested by Western blot. The results showed that Celecoxib inhibited the proliferation of both MV4-11 and K562 cells, but the IC50 for MV4-11 was (29.14 ± 2.4) µmol/L, which was significantly lower than that of K562 cells (39.84 ± 1.0) µmol/L (P < 0.05); The induced apoptosis rate of Celecoxib at 20-80 µmol/L on MV4-11 was not observed, but there was apparent influence on K562 at the same concentration. Western blot showed that Celecoxib down-regulated the expression of MEK and Mcl-1 but did not change the expression of pAKT obviously on MV4-11 cells, while the expression of Mcl-1 was reduced a little, but no obvious change were found in the expression of MEK and pAKT on K562 cells. It is concluded that the Celecoxib can inhibit the proliferation of FLT3-ITD positive AML cells distinctly, and the potential mechanism may be related to the inhibition of the MEK/Mcl-1 signaling pathway.